Skip to main content
Log in

Oral Paricalcitol

A Viewpoint by James B. Wetmore and L. Darryl Quarles

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Treatments in Endocrinology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43(3): 572–9

    Article  PubMed  Google Scholar 

  2. National Kidney Foundation (NFK) K/DOQI Guidelines. K/DOQI clinical practise guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 Suppl. 3: S1–201

    Google Scholar 

  3. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349(5): 446–56

    Article  PubMed  CAS  Google Scholar 

  4. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Kidney Dis 2006 Feb; 47(2): 263–76

    Article  PubMed  CAS  Google Scholar 

  5. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4): 1483–90

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wetmore, J.B., Quarles, L.D. Oral Paricalcitol. Treat Endocrinol 5, 326 (2006). https://doi.org/10.2165/00024677-200605050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200605050-00006

Navigation